NIBRT Cell Gene Therapy Project

Centre of excellence in biopharma manufacturing

Ireland has established a hard won reputation as a centre of excellence in biopharma manufacturing mainly focused on monoclonal antibodies. However, the new wave of biopharma investments will include next generation biologics (mainly CGTs) which represent complex challenges to manufacture economically. NIBRT and its partners established a CGT Forum in December 2018 to address these challenges, publishing a White Paper in May 2019, announced several CGT research collaborations and commenced CGT training activity in Q4 2019.

Workforce development

To further facilitate CGT training and research, NIBRT has appointed PM Group to develop a design to expand NIBRT’s existing facility in Dublin, Ireland. With this expansion NIBRT will be able to support the workforce development and research expertise that underpins global CGT manufacturing investments.

Innovating CGT facilities

“PM Group is delighted to be appointed to work on the concept design of NIBRT’s new CGT training facility. It is an exciting next step and builds on our track record of innovation in the CGT space and our partnership with NIBRT,” said Eileen Lee, Dublin Office Operations Manager, PM Group

Announcing the appointment of PM Group NIBRT CEO, Dominic Carolan stated “We are delighted to partner with the PM Group, who are renowned leading experts in the provision of facilities for CGT manufacturing. This design will position NIBRT to train our industry and educational clients in the current and emergent CGT manufacturing technologies as well as continuing expansion of our CGT research activities.”

Pictured above from left to right: from NIBRT - John Milne, Rosari McCarthy, Dominic Carolan with from PM Group - Eileen Lee,Tom Bannon and Leonard Sheil.

Learn more about the work we are doing to introduce robotics to Cell Gene Therapy facilities.